A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
PHASE2CompletedINTERVENTIONAL
Enrollment
23
Participants
Timeline
Start Date
June 30, 2013
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Conditions
Chronic Hepatitis CCHCHCVHepatitis C
Interventions
DRUG
VX-135
DRUG
Daclatasvir
Trial Locations (2)
Unknown
New Zealand, Auckland
New Zealand, Christchurch
All Listed Sponsors
lead
Vertex Pharmaceuticals Incorporated
INDUSTRY
NCT01842451 - A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C | Biotech Hunter | Biotech Hunter